- Improved neurologic outcome in young adults (18-39 years) with Ronopterin infused early
- Significantly less aggressive critical care with maintained renal function in young adults
- New patent filed for efficacious treatment window
- Discussions with US and EU regulators to support market authorization initiated
vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases, today announces the combined post hoc analyses of the phase 2 (NOSTRA) and phase 3 clinical trials (NOSTRA III) of Ronopterin (formerly VAS203) for the treatment of traumatic brain injury (TBI). These analyses expand on the clinically meaningful results in patients with moderate and severe TBI with early infusion of Ronopterin, starting between 6 and 12 hours after TBI. Ronopterin has the potential to be the first successful drug therapy for TBI with meaningful improvements in neurologic outcome.